ACR Roundup: JAK Safety Shown Across Multiple Trials

Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.

Rheumatology

The highlights of the recent American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting tended to be data for approved drugs and therapies in later-stage development that back up previously reported efficacy or provide assurances about safety in rheumatoid and psoriatic arthritis and other autoimmune diseases.

Those kinds of data are important for prescribers and patients, offering points of differentiation in indications with a growing number...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

Stada And Bio-Thera Add To Biosimilars Alliance With Tocilizumab

 
• By 

Stada and Bio-Thera Solutions have added another product to their biosimilars partnership, with the Chinese developer’s tocilizumab rival to Roche’s RoActemra set to be marketed by the German giant in Europe.

EU Industry Welcomes Generics Exemption From US Tariffs

 
• By 

The European generics industry has welcomed news that generic medicines will be exempt from tariffs under the latest EU-US trade agreement.

‘It Validates Adalvo‘ – CEO Anil Okay Talks EQT Takeover

 
• By 

In the wake of a major transaction that saw private-equity firm EQT take control of Alvo group B2B business Adalvo, CEO Anil Okay talks to Generics Bulletin about what the deal means for Adalvo and how it is planning to expand in future.

Building A Biosimilar ‘Launch Machine’ For MENA – MS Pharma CEO Sets Out Strategy

 
• By 

MENA specialist MS Pharma has been building up a portfolio of licensed biosimilars in recent years to build on its generics roots, seeking a first-mover advantage in key markets as well as benefiting from local manufacturing operations. Chief executive Kalle Känd sets out the firm’s strategy.

More from Generics Bulletin

Aeon Expects Imminent Data On Botox Biosimilar

 
• By 

Aeon Biopharma says it expects to complete primary structure and select functional analyses for its ABP-450 proposed biosimilar to Botox by the end of the current quarter, ahead of a meeting with the FDA in late 2025 to discuss next steps.

ANI Raises Guidance Once More But Admits Generics Sales Will Soften In H2

 
• By 

ANI insisted that it would continue to invest in Generics R&D to keep up a cadence of launches, following another strong quarter on the back of generic prucalopride and its Cortrophin Gel.

Viatris Locks Cipla Out Of Generic Yupelri Market Until 2039

 
• By 

Cipla has reached a settlement with Theravance Biopharma and Viatris regarding its proposed generic version of Yupelri (revefenacin) once-daily nebulized inhalation solution. Under the agreement, Cipla will not introduce its product into the US market prior to April 2039.